New combo therapy for High-Risk breast cancer enters safety testing
Disease control
Not yet recruiting
This early-phase trial will test the safety and tolerability of combining a CDK4/6 inhibitor (abemaciclib) with radiation therapy after surgery in 30 women with HR+/HER2- high-risk breast cancer. The study aims to find the highest safe dose of the drug when used alongside radiati…
Phase: EARLY_PHASE1 • Sponsor: Guizhou Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC